We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Mindray Displays New Generation Benchtop Cellular Analysis Line

By LabMedica International staff writers
Posted on 31 Jan 2019

Image: The CAL 6000 benchtop cellular analysis line (Photo courtesy of Mindray).

Image: The CAL 6000 benchtop cellular analysis line (Photo courtesy of Mindray).

Mindray (Shenzhen, China) exhibited its new generation benchtop cellular analysis line at MedLab Middle East, an international platform for laboratory management and medicine that brought together more than 700 exhibitors and over 35,000 professionals. MedLab Middle East 2019 took place at the Dubai International Convention and Exhibition Centre, Dubai, UAE from the 4th to the 7th of February.

Among Mindray’s latest innovations displayed at MedLab Middle East 2019 was CAL 6000, a benchtop cellular analysis line that connects two units of BC-6000 or BC-6200 auto hematology analyzers and one unit of SC-120 auto slide maker & stainer. The compact workstation helps save more laboratory space while delivering a fast throughput of up to 220 samples and 120 slides per hour. It provides automated body fluids test results, and is equipped with labXpert data management software for automatic sample validation and analysis.

At MedLab Middle East 2019, Mindray also exhibited the CL-900i chemiluminescence immunoassay analyzer, which has an industry-leading small benchtop footprint, a throughput of up to 180 tests per hour and 15 reagent positions. The CL-900i is a state-of-the-art system that is compact, fast and accurate, offering automation and reliable performance to ensure quality testing results with minimal hands-on time.

Visit expo >

New

Gold Member

Nucleic Acid Extractor System

NEOS-96 XT

New

Gold Member

Automatic Hematology Analyzer

CF9600

New

HPV Test

Allplex HPV28 Detection

New

CMV CLIA Diagnostic

CLIA CMV IgA Screen Group

Latest MEDLAB 2019 News

Channels

Clinical Chemistry

view channel

Blood Test Detects Testicular Cancer Missed by Standard Markers

Testicular cancer most often affects adolescents and young adults and is highly treatable when found early. Diagnosis can be difficult when tumors do not produce sufficient levels of standard blood-based... Read more

Routine Blood Tests Identify Biomarkers Linked to PTSD

Post-traumatic stress disorder (PTSD) is associated with a range of chronic physical health conditions and affects multiple organ systems. Clinical laboratories routinely measure blood analytes that reflect... Read more

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk

Alzheimer’s disease and related dementias develop over years, making it difficult to identify at-risk patients before symptoms appear. Clinicians therefore need widely available laboratory markers that... Read more

Molecular Diagnostics

view channel

Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions

Cardiovascular disease is the leading cause of death worldwide, yet many at‑risk individuals are overlooked by traditional calculators. Tools that weigh age, sex, blood pressure, and cholesterol can miss... Read more

Routine Genetic Marker May Help Guide Targeted Therapy in Acute Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer with widely variable treatment outcomes between patients. Choosing which individuals will benefit from targeted agents remains difficult, limiting... Read more

Proteomic Risk Score Predicts Kidney Disease Progression in High-Risk Patients

Chronic kidney disease progression is difficult to anticipate, limiting opportunities to intervene before irreversible decline. Risk assessment is especially uncertain for people who carry high‑risk variants... Read more

Image: Graphical abstract (Jessica L. Corredor et al., The American Journal of Human Genetics (2026). DOI: 10.1016/j.ajhg.2026.03.014)

Risk Prediction Tool Enhances Genetic Testing for Li-Fraumeni Syndrome

Li-Fraumeni syndrome is a rare hereditary cancer predisposition most often driven by germline mutations in the TP53 tumor suppressor gene. Determining who should receive TP53 testing remains challenging... Read more

Hematology

view channel

Advanced CBC-Derived Indices Integrated into Hematology Platforms

Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more

Blood Test Enables Early Detection of Multiple Myeloma Relapse

Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read more

Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching

CareDx (Brisbane, CA, USA) has introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO genotyping solution unveiled at the European Federation for Immunogenetics (EFI) Conference 2026.... Read more

Image: Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior (photo courtesy of Shutterstock)

Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior. Although many patients respond to standard chemotherapy with... Read more

Immunology

view channel

Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection

Accurate laboratory diagnosis of early Lyme disease remains challenging because serologic responses may be limited soon after infection. Missed detection at this stage can delay evaluation and management... Read more

Image: Graphical abstract - Human immune aging clock identifies RUNX1 as a decelerator of T cell senescence (photo courtesy of Zhang Weiqi)

Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target

Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more

Study Finds Influenza Often Undiagnosed in Winter Deaths

Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read more

Combined Screening Approach Identifies Early Leprosy Cases

Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more

Microbiology

view channel

Image: Biosensor for tuberculosis detection (photo courtesy of UPV)

Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour

Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more

Image: Graphical abstract (Qin, Y. et al., Cell Rep Med 7: 102761 (2026). DOI: 10.1016/j.xcrm.2026.102761)

Oral–Gut Microbiome Signatures Identify Early Gastric Cancer

Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read more

Image: Magnetic field-enhanced alignment and detection of hemozoin in lysed infected red blood cells using polarizing microscopy (photo courtesy of Dickson Mwenda Kinyua, Kirinyaga University)

Label-Free Microscopy Methodd Enables Faster, Quantitative Detection of Malaria

Microscopy of blood smears remains a cornerstone for malaria diagnosis but can be slow, stain-dependent, and operator intensive. With more than 200 million infections and over 600,000 deaths annually,... Read more

Gut Microbiome Test Predicts Melanoma Recurrence After Surgery

Melanoma remains prone to relapse even after surgery and adjuvant immunotherapy, with 25% to 40% of patients experiencing recurrence. Clinicians lack reliable pre-treatment indicators to identify those... Read more

Pathology

view channel

Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more

Image: Overview of the MorphoGenie framework (Murthy, R.S., Stassen, S.V., Siu, D.M.D. et al. Nat Commun 16, 11465 (2025). doi.org/10.1038/s41467-025-66267-w)

Interpretable AI Reveals Hidden Cellular Features from Microscopy Images

Microscopy images contain rich clues about cell health, but many disease-relevant morphological differences are too subtle to see and difficult to quantify consistently. Artificial intelligence (AI) has... Read more

Tumor Immune Structure Predicts Response to Immunotherapy in Melanoma

Many patients with advanced melanoma start on anti-PD-1 immunotherapy, but responses can wane or never develop. Clinicians often turn to anti-CTLA-4 after resistance emerges, yet predicting who will respond... Read more

Image: The PRET system provides an integrated solution for multiple pathology diagnostic tasks, including cancer screening, tumor subtyping, tumor segmentation, and lymph node metastasis detection (Li, Y., Ning, Z., Xiang, T. et al. Nature Cancer (2026). doi.org/10.1038/s43018-026-01141-2)

Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides

Pathologists are essential for cancer diagnosis and treatment planning, yet a global workforce shortage is straining services. Nearly 20 million new cases are diagnosed each year, and traditional artificial... Read more

Technology

view channel

Microfluidic Single-Cell Assay Predicts Breast Cancer Risk

Risk stratification for breast cancer remains imprecise, as population-based models and breast density can over- or underestimate individual risk, potentially leading to over- or under-screening.... Read more

AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer

Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more

Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing

Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read more

Noninvasive Sputum Test Detects Early Lung Cancer

Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more

Industry

view channel

CareDx Expands Precision Oncology Portfolio with Naveris Acquisition

CareDx Inc. (Brisbane, CA, USA), a precision medicine company advancing clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, has entered a definitive agreement... Read more

Thermo Fisher Scientific to Sell Microbiology Business to Astorg

Thermo Fisher Scientific has signed a definitive agreement to sell its microbiology business to Astorg for approximately $1.075 billion, comprising cash and a $50 million seller note. Announced on April... Read more

Collaboration Expands Access to Rapid Metagenomic Diagnostics for Complex Infections

Hospitals are seeing rising rates of complicated and healthcare-associated infections, especially in immunocompromised patients, intensifying the need for rapid, comprehensive pathogen detection.... Read more

Image: The acquisition adds the LEX VELO System to QuidelOrtho’s portfolio (photo courtesy of LEX Diagnostics)

QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition

QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more